There are plenty of blue chips trading on the ASX 200 index. But which ones could be top buys?
Let's take a look at three that analysts are recommending as buys right now. They are as follows:
CSL Ltd (ASX: CSL)
The team at Bell Potter thinks that now could be a good time to buy CSL's shares.
The broker highlights that the ASX 200 blue chip share is trading at an attractive level for investors. Especially given its belief that the biotechnology company's earnings growth is about to accelerate. It said:
CSL presents an attractive buying opportunity as we anticipate the start of a margin recovery phase for CSL, driving above-market earnings growth over the next few years. CSL trades at a 12-month forward PE of ~28x, representing a discount to its 10-year average of ~31x. Furthermore, the company will continue to deleverage the balance sheet over the next few years. Given the company's proven quality and growth prospects, we believe significant upside remains.
James Hardie Industries plc (ASX: JHX)
Another ASX 200 blue chip share that could be a buy according to analysts at Bell Potter is building materials company James Hardie.
It likes the company due to the structural shift towards fibre cement in the United States. The broker expects this to support an earnings expansion. It said:
In our view, James Hardie is poised for continued earnings expansion, driven by the structural shift towards fibre cement in the US. Households in the US continue to shift to fibre cement cladding from vinyl/timber, providing a multi- year runway for JHX's revenue and profit growth. With a strong market position, premium brand, and pricing power, JHX is poised to capitalise on structural growth in the fibre cement market and cyclical tailwinds from potential rate cuts.
ResMed Inc. (ASX: RMD)
Finally, analysts at Catapult Wealth think that ResMed could be an ASX 200 blue chip share to buy.
Its analysts have been impressed with the company's performance so far in FY 2025 and believe there's more to come. Particularly given the size of the sleep apnoea market. Its analysts told the Bull:
ResMed posted a top first quarter result in fiscal year 2025. Income from operations was up 34 per cent on the prior corresponding period, which was well above previous guidance. Revenue was up 11 per cent. ResMed provides sleep apnoea solutions in a market with strong growth potential. Awareness and diagnosis of sleep apnoea continues to grow, but only a small percentage of potential patients are receiving treatment. Consequently, this represents a huge opportunity for ResMed. Fears that new weight loss and diabetes drugs would impact the business continue to ease, and, in our view, pose limited risk.
